TLSI stock icon

TriSalus Life Sciences
TLSI

$5.40
3.65%

Market Cap: 158M

 

About: TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.

0
Funds holding %
of 6,702 funds
0
Analysts bullish %
of 3 analysts
0
News positive %
of 3 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

233% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 3

57% more capital invested

Capital invested by funds: $5.74M [Q4 2023] → $9.03M (+$3.29M) [Q1 2024]

37% more funds holding

Funds holding: 19 [Q4 2023] → 26 (+7) [Q1 2024]

20% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 5

0.93% more ownership

Funds ownership: 2.57% [Q4 2023] → 3.51% (+0.93%) [Q1 2024]

Research analyst outlook

3 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$12
122%
upside
Avg. target
$13.33
147%
upside
High target
$16
196%
upside

3 analyst ratings

positive
100%
neutral
0%
negative
0%
Canaccord Genuity
William Plovanic
122%upside
$12
Buy
Maintained
27 Jun 2024
Canaccord Genuity
William Plovanic
122%upside
$12
Buy
Initiated
30 May 2024
JonesTrading
Justin Walsh
196%upside
$16
Buy
Initiated
10 May 2024

Financial journalist opinion

Based on 3 articles about TLSI published over the past 30 days